Tempus AI to acquire cancer-testing company Personalis for $1.5 billion

American Health Intel

Rules · Money · Medicine · Decoded daily

Tempus AI to acquire cancer-testing company Personalis for $1.5 billion

Plus: InMode special committee update reveals Steel Partners' first 100% buyout bid. The day's rules, money, and enforcement, sourced and tiered below.

Record

Tempus AI, a health data and AI company, just agreed to pay 1.5 billion dollars for Personalis, maker of a test that detects cancer recurrence from trace DNA in the blood. Investors punished the buyer, not the seller.

Tempus is paying $16.25 a share, a 6% premium to Friday's close, and will fold Personalis's cancer-monitoring test into its AI platform. Tempus shares fell as much as 8% on the news. Expected to close late 2026 or early 2027.

Record

InMode, the medical-aesthetic device maker fighting over who gets to buy it, told shareholders yesterday its board is still weighing two rival bids, a day after a court deadline passed with no ruling.

The committee revealed this is the first time Steel Partners offered to buy 100% of InMode, not just a majority stake. Steel separately accused the CEO of governance failures, including cutting guidance before selling shares at higher prices.

Also today

Novo Nordisk sues Eli Lilly over Zepbound and Mounjaro advertising claims Read
Healthcare staffing industry returns to growth in 2026 after FTC blocks biggest merger Read

Pick your field on the site and every story tells you what it means for you.

Reply to this email and tell us what you want covered. We read everything.

We show our work. We score our own calls.

Track record · Calendar · Enforcement · X · LinkedIn

News and analysis, not legal, medical, coding, or investment advice.
You subscribed at americanhealthintel.com · Unsubscribe